North Carolina urges HHS to license Novo and Lilly obesity drugs as a way to lower costs

Taking stock of the drug industry, from the lab to the medicine chest

August 6, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Scott Olson/Getty Images STAT+ | North Carolina urges HHS to license Novo and Lilly obesity drugs as a way to lower costs "This is a problem that needs a federal solution," North Carolina Treasurer Dale Folwell wrote to the Biden administration. By Ed Silverman STAT+ | 'Jerking families around': Canceled Roche rare disease trial devastates parents, angers researchers The abrupt decision stunned parents of children enrolled in the study of basmisanil, as well as the academic researchers running it. By Elizabeth Cohen STAT+ | Biotech VCs are pacing for another record-low year of fundraising amid glimpses of recovery Just released: STAT's fifth annual report ranking biotechnology venture capital firms. Find out which VCs are delivering the best returns in 2024. By Allison DeAngelis Courtesy Symbiotic Capital STAT+ | Biotech mogul Arie Belldegrun extends empire with launch of $600 million credit firm Symbiotic Capital will provide loans to companies including biotechs, manufacturers of medical devices and health care tools, and sequencing firms. By Allison DeAngelis STAT+ | BioMarin to restrict hemophilia therapy to three countries, seeking to overcome slow sales The gene therapy, called Roctavian, was approved in Europe in 2022 and in the U.S. in 2023. In the second quarter, the company treated only five patients. By Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser